Practical experience using galectin-3 in heart failure

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 10, 2014, Pages 1425-1431

  McCullough, Peter A ^a,b,c  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c The Heart Hospital   (United States)

Author keywords

Biomarker; Case management; Galectin 3; Heart failure; Hospitalization; Mortality

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; BRAIN NATRIURETIC PEPTIDE; CHLORTALIDONE; ENALAPRIL; GALECTIN 3; GELATINASE A; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SPIRONOLACTONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TROPONIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ANTERIOR MYOCARDIAL INFARCTION; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CASE REPORT; CEREBROVASCULAR ACCIDENT; DEFIBRILLATOR; DIASTOLIC DYSFUNCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPNEA; ECHOCARDIOGRAPHY; FATIGUE; FEMALE; HEART DEATH; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART MUSCLE PERFUSION; HEART SCINTISCANNING; HUMAN; HYPERTENSION; INTENSIVE CARE UNIT; ISCHEMIC CARDIOMYOPATHY; LUNG EDEMA; MALE; MIDDLE AGED; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINUS RHYTHM; VASCULAR FIBROSIS; BLOOD; FIBROSIS; HEART STROKE VOLUME; PATHOPHYSIOLOGY; RISK;

ACUTE CORONARY SYNDROME; FIBROSIS; GALECTIN 3; HEART FAILURE; HUMANS; RISK; STROKE VOLUME;

EID: 84919811777     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0278     Document Type: Review

References (29)

1. Raghava V, Ramachandran V. Epidemiology of heart failure. In: Mann DL, editor. Heart failure: a companion to Braunwald's heart disease, 2nd ed. Saint Louis, Missouri: Elsevier Saunders, 2011.
2. McMurray, J. What is heart failure? In: Abraham W, Krum H, editors. Heart failure: a practical approach to treatment. New York, New York: McGraw Hill, 2007.
3. Vasquez C, Benamer N, Morley GE. The cardiac fibroblast: functional and electrophysiological considerations in healthy and diseased heart. J Cardiovasc Pharmacol 2011;57:380-8.
4. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 2002;39:60-9.
5. Soman P, Lahiri A, Mieres JH, Calnon DA, Wolinsky D, Beller GA, et al. Etiology and pathophysiology of new-onset heart failure: evaluation by myocardial perfusion imaging. J Nucl Cardiol 2009;16:82-91.
6. van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol 2010;7:30-7.
7. Vanhecke TE, Kim R, Raheem SZ, McCullough PA. Myocardial ischemia in patients with diastolic dysfunction and heart failure. Curr Cardiol Rep 2010;12:216-22.
8. Vanhecke TE, Franklin BA, Soman P, Lahiri A, Mieres JH, Sias T, et al. Influence of myocardial ischemia on outcomes in patients with systolic versus non-systolic heart failure. Am J Cardiovasc Dis 2011;1:167-75.
9. Michels VV, Moll PP, Miller FA, Tajik AJ, Chu JS, Driscoll DJ, et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med 1992;326:77-82.
10. Hutchinson KR, Stewart JA Jr, Lucchesi PA. Extracellular matrix remodeling during the progression of volume overload-induced heart failure. J Mol Cell Cardiol 2010;48:564-9.
11. Tumlin JA, Costanzo MR, Chawla LS, Herzog CA, Kellum JA, McCullough PA, et al. Cardiorenal syndrome type 4: insights on clinical presentation and pathophysiology from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 2013;182:158-73.
12. McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med 2011;12:200-10.
13. Creemers EE, Pinto YM. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res 2011;89:265-72.
14. Cooper DN. Galectinomics: finding themes in complexity. Biochim Biophys Acta 2002;1572:209-31.
15. Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006;1760:616-35.
16. Krzes̈lak A, Lipińska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett 2004;9:305-28.
17. Raimond J, Zimonjic DB, Mignon C, Mattei M, Popescu NC, Monsigny M, et al. Mapping of the galectin-3 gene (LGALS3) to human chromosome 14 at region 14q21-22. Mamm Genome 1997;8:706-7.
18. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev 2009;230:160-71.
19. Liu YH, D'Ambrosio M, Liao TD, Peng H, Rhaleb NE, Sharma U, et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 2009;296:H404-12.
20. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004;110:3121-8.
21. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 2012;60:1249-56.
22. Djoussé L, Matsumoto C, Petrone A, Weir NL, Tsai MY, Gaziano JM. Plasma galectin 3 and heart failure risk in the Physicians' Health Study. Eur J Heart Fail 2014;16:350-4.
23. Grandin EW, Jarolim P, Murphy SA, Ritterova L, Cannon CP, Braunwald E, et al. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem 2012;58:267-73.
24. Lin YH, Lin LY, Wu YW, Chien KL, Lee CM, Hsu RB, et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009;409:96-9.
25. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006;48:1217-24.
26. van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail 2013;6:219-26.
27. Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, et al. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Am Heart J 2012;164:878-83.
28. Wu AH, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 2004;6:355-8.
29. Shenkman HJ, Pampati V, Khandelwal AK, McKinnon J, Nori D, Kaatz S, et al. Congestive heart failure and QRS duration: establishing prognosis study. Chest 2002;122:528-34.